| The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria |
190 |
| Epidemiology of atopic dermatitis in adults: Results from an international survey |
91 |
| EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis |
78 |
| The international WAO/EAACI guideline for the management of hereditary angioedemaThe 2017 revision and update |
71 |
| EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy |
68 |
| Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)a EAACI position paper |
56 |
| High levels of butyrate and propionate in early life are associated with protection against atopy |
51 |
| EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy |
47 |
| EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma |
40 |
| Hereditary angioedema with a mutation in the plasminogen gene |
38 |
| EAACI Position paper on the standardization of nasal allergen challenges |
37 |
| EUFOREA consensus on biologics for CRSwNP with or without asthma |
36 |
| 2019 ARIA Care pathways for allergen immunotherapy |
35 |
| Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis |
32 |
| Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin |
32 |
| Perspectives in allergen immunotherapy: 2019 and beyond |
32 |
| Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: The one airway concept revisited |
32 |
| Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes |
31 |
| Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma |
31 |
| Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis |
31 |
| The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change |
30 |
| EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity |
30 |
| Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis |
29 |
| Asthma in the elderly and late-onset adult asthma |
28 |
| Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study |
27 |
| A biodiversity hypothesis |
26 |
| Immune pathomechanism and classification of drug hypersensitivity |
26 |
| Bronchiolitis needs a revisit: Distinguishing between virus entities and their treatments |
26 |
| Tight junction, mucin, and inflammasome-related molecules are differentially expressed in eosinophilic, mixed, and neutrophilic experimental asthma in mice |
25 |
| Birch pollen allergy in Europe |
25 |
| The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma |
25 |
| An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions |
24 |
| The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies |
24 |
| Comorbid treatable traits in difficult asthma: Current evidence and clinical evaluation |
23 |
| Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma |
23 |
| Toward clinically applicable biomarkers for asthma: An EAACI position paper |
23 |
| Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products |
22 |
| Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications |
22 |
| ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma |
22 |
| Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy |
22 |
| Recent developments and highlights in mechanisms of allergic diseases: Microbiome |
21 |
| The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study |
21 |
| Thinking bigger: How early-life environmental exposures shape the gut microbiome and influence the development of asthma and allergic disease |
21 |
| Eosinophils capture viruses, a capacity that is defective in asthma |
21 |
| Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study |
20 |
| Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide |
20 |
| Mobile health tools for the management of chronic respiratory diseases |
20 |
| Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children |
20 |
| Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma |
20 |
| Allergens displayed on virus-like particles are highly immunogenic but fail to activate human mast cells |
20 |
